51黑料吃瓜在线观看,51黑料官网|51黑料捷克街头搭讪_51黑料入口最新视频

本文首先對超聲造影劑（UCA）的定義、發(fā)展、結構特點以及臨床應用現(xiàn)狀等進行概述，重點介紹了UCA在超聲診斷和超聲治療方面的應用現(xiàn)狀，然后探討了UCA安全性問題，最后介紹了納米級UCA等最新研究進展。本文對全面了解UCA特性、應用及安全性問題具有重要參考價值。

［1］Gramiak R，Shah P.Echocardiography of the aortic root ［J］.Investigative Radiology，1968，3:356-366.
［2］Hughes MS，Lanza GM，Marsh JN,et al.Targeted ultrasonic contrast agents for molecular imaging and therapy:a brief review［J］.MEDICA，2003，47:66-73.
［3］Schneider M.Molecular imaging and ultrasound-assisted drug delivery［J］.Journal of Endourology，2008，22(4):795-802.
［4］Armstrong WF，Ryan T.Stress echocardiography from 1979 to present ［J］.Journal of the American Society of Echocardiography，2008，21:22–28.
［5］Kaneko Y，Maruyama T，Takegami K，et al.Use of a microbubble agent to  increase the effects of high intensity focused ultrasound on liver tissue［J］.European Radiology，2005，15:1415–1420.
［6］Quaia E，Palumbo A，Rossi S,et al.Characterization of liver tumors insonated at low transmit power after microbubble contrast agent injection:comparison of visual and quantitative analysis in diagnostic performance［J］.AJR Am J Roentgenol，2006，186:1560–1570.
［7］Piscaglia F，Corradi F，Mancini M,et al.Real time contrast enhanced ultrasonography (CEUS) in detection of liver metastases from gastrointestinal cancer［J］.BMC Cancer，2007，7:171–184.
［8］Quaia ED，Onofrio M，Palumbo A，et al.Comparison of contrast-enhanced Ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver:diagnostic performance and confidence［J］.European Radiology，2006，16:1599–1609.
［9］Wilson SR，Burns PN.An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse inversion sonography ［J］.AJR Am J Roentgenol，2006，86:1401–1412.
［10］David Cosgrove，Chris Harvey.Clinical uses of microbubbles in diagnosis and treatment ［J］.Med Biol Eng Comput，2009，47:813–826.
［11］Behm C，Lindner J.Cellular and molecular imaging with targeted contrast ultrasound［J］.Ultrasound Quarterly，2006，22(1):67–72.
［12］華興，高云華.超聲波與聲學造影劑在溶栓中的作用［J］.臨床超聲醫(yī)學雜志，2006，(7):425-427.
［13］Alonso A，Della Martina A，Stroick M,et al.Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound［J］ .Stroke，2007，38:1508–1514.
［14］陳松.納米液態(tài)氟碳微球超聲造影劑的制備及體外尋靶實驗研究［D］.重慶：重慶醫(yī)科大學，2008.
［15］Yanagisawa K，Moriyasu F，Miyahara T，et al.Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells［J］.Ultrasound Med Biol，2007，33:318–325.
［16］Gail ter Haar.Safety and bio-effects of ultrasound contrast agent［J］.Medical and Biological Engineering and Computing，2009，47:893–900.
［17］Miller DL，Averkiou MA，Brayman AA,et al.Bioeffects considerations for diagnostic ultrasound contrast agents［J］.J Ultrasound Med，2008，27:611–632.
［18］Barnett SB，Duck F，Ziskin M.WFUMB symposium on safety of ultrasound in medicine:conclusions and recommendations on biological effects and safety of ultrasound contrast agents，2006［J］.Ultrasound Med Biol，2007，33:233–234.
［19］Main ML，Goldman JH，Grayburn PA.Thinking outside the “box”-the ultrasound contrast controversy［J］.Journal of the American College of Cardiology，2007，50:2434–2437.
［20］Kusnetzky L，Khalid A，Khumri T,et al.Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent:results in 18，671 consecutive studies［J］.Journal of the American College of Cardiology，2008，51:1704–1706.
［21］Duck F.Hazards，risks and safety of diagnostic ultrasound［J］.Med Eng Phys，2008，30:1338–1348.
［22］Dijkmans P，Visser C，Kamp O.Adverse reactions to ultrasound contrast agents:is the risk worth the benefit? ［J］.European Journal of Echocardiography，2005，6(5):363–366.
［23］Claudon M，Cosgrove D，Albrecht T,et al.Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS)—update 2008［J］.Ultraschall Med，2008，29:28–44.